Cantor Fitzgerald Predicts Weaker Earnings for Arcellx

Arcellx, Inc. (NASDAQ:ACLX) – Investment analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Arcellx in a research note issued to investors on Thursday, October 9th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will earn ($3.72) per share for the year, down from their prior estimate of ($2.98). Cantor Fitzgerald currently has a “Hold” rating and a $88.00 price objective on the stock. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx’s FY2026 earnings at ($3.56) EPS.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.94) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $16.76 million. Arcellx had a negative net margin of 329.93% and a negative return on equity of 43.04%.

Other research analysts also recently issued research reports about the stock. Citigroup initiated coverage on shares of Arcellx in a research report on Tuesday, June 17th. They issued a “buy” rating and a $110.00 price objective for the company. Scotiabank upped their price objective on shares of Arcellx from $93.00 to $133.00 and gave the stock a “sector outperform” rating in a research report on Thursday, July 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Arcellx presently has a consensus rating of “Moderate Buy” and an average target price of $112.69.

Arcellx Stock Performance

Shares of Arcellx stock opened at $87.33 on Monday. The firm has a 50-day simple moving average of $76.01 and a two-hundred day simple moving average of $68.26. The company has a market cap of $4.84 billion, a P/E ratio of -25.54 and a beta of 0.31. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $107.37.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 21,034 shares of the stock in a transaction dated Tuesday, September 30th. The shares were sold at an average price of $81.28, for a total value of $1,709,643.52. Following the completion of the sale, the insider owned 624 shares in the company, valued at approximately $50,718.72. This represents a 97.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders have sold 37,146 shares of company stock valued at $3,000,136. 8.35% of the stock is currently owned by corporate insiders.

Institutional Trading of Arcellx

Hedge funds have recently bought and sold shares of the business. State of Wyoming acquired a new stake in Arcellx in the 2nd quarter valued at about $28,000. GAMMA Investing LLC raised its holdings in Arcellx by 104.1% in the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company’s stock valued at $32,000 after acquiring an additional 252 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock valued at $49,000 after acquiring an additional 486 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Arcellx in the 1st quarter valued at about $50,000. Finally, GF Fund Management CO. LTD. raised its holdings in Arcellx by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,384 shares of the company’s stock valued at $91,000 after acquiring an additional 249 shares during the last quarter. Institutional investors and hedge funds own 96.03% of the company’s stock.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).